NCT03092999View on ClinicalTrials.gov

Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1002670 (Vilaprisan)

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

March 28, 2017

Primary Completion Date

July 17, 2017

Study Completion Date

July 17, 2017

Conditions
Leiomyoma
Interventions
DRUG

Vilaprisan (BAY1002670)

2 mg tablet, single dose, oral administration

Trial Locations (2)

23538

Universitätsklinikum Schleswig-Holstein / AÖR, Lübeck

24105

CRS Clinical-Research-Services Kiel GmbH, Kiel

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY